^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KDM5D overexpression

    i
    Other names: KDM5D, Lysine Demethylase 5D, Jumonji, AT Rich Interactive Domain 1D (RBP2-Like), [Histone H3]-Trimethyl-L-Lysine(4) Demethylase 5D, Jumonji/ARID Domain-Containing Protein 1D, Lysine (K)-Specific Demethylase 5D, Lysine-Specific Demethylase 5D, Histocompatibility Y Antigen, Histone Demethylase JARID1D, Protein SmcY, JARID1D, SMCY, HYA, H-Y, HY, Epididymis Secretory Sperm Binding Protein, Selected Mouse CDNA On Y, Human Homolog Of, Jumonji, AT Rich Interactive Domain 1D, Smcy Homolog, Y-Linked (Mo
    Entrez ID:
    8284
    Related biomarkers:
    CNA
    2ms
    Histone demethylase KDM5D represses the proliferation, migration and invasion of hepatocellular carcinoma through the E2F1/TNNC1 axis. (PubMed, Antioxid Redox Signal)
    KDM5D inhibits E2F1 expression by suppressing H3K4me3 modification in the E2F1 promoter region, which in turn suppresses the binding of E2F1 to the TNNC1 promoter region, thus leading to the inhibition of HCC development.
    Journal • Epigenetic controller
    |
    KDM5D (Lysine Demethylase 5D) • E2F1 (E2F transcription factor 1)
    |
    KDM5D overexpression
    1year
    KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe. (PubMed, Int J Mol Sci)
    The cotreatment of cisplatin and barasertib suppressed tumor growth in the tumor mouse model. Thus, KDM5D might be involved in the development of persister cells, and AURKB disruption can overcome tolerance to platinum treatment in HNSCC.
    Journal • Epigenetic controller
    |
    AURKB (Aurora Kinase B) • KDM5D (Lysine Demethylase 5D)
    |
    KDM5D overexpression
    |
    cisplatin • barasertib (AZD1152)